Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2022 call → NOWe need to determine if the company is currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event that ends the wait, and that the cost is real and current, and management treats it as the main work. Let's analyze the transcript. The company is Adaptive Biotechnologies. They have two businesses: MRD and Immune Medicine. In MRD, they have clonoSEQ tests. They are growing volumes, expanding sales force, launching DLBCL, Epic integration. In Immune Medicine, they have pharma services and drug discovery. They have a partnership with Genentech for cell therapy. They mention that they are waiting for Genentech to advance the first candidate into the clinic. They have delivered two additional shared TCR data packages. They are also working on internal programs in autoimmune disorders. Key points: They have a Genentech collaboration. They mention that they recognized a $2 million milestone from approval of a multiple myeloma therapy. They have a royalty financing agreement with OrbiMed. They have cash of $498 million. The question: Does management describe the company as currently living through a defined waiting period it is paying for out of its own pocket? That is, is there a real ongoing cash or earnings cost for something whose benefit has not arrived yet, and the end of that waiting period is a specific near-dated event? Look for evidence: They are investing in drug discovery, with Genentech. They are waiting for IND acceptance. They mention that the IND acceptance is a big swing factor toward the end of the year. They also mention that they are focusing on speed to clinic for the first shared TCR candidate. They have delivered two additional data packages. They are also working on internal programs. But is there a cost currently being borne? They have R&D expenses, but that's normal. They are not necessarily describing a "waiting period" where they are paying for something that will start earning later. They are growing revenue, they have revenue from pharma services, etc. They are not in a situation where they are paying for a facility or a launch that hasn't happened yet. They are investing in growth, but that's typical.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.